PATENT

## IAP9 Ree'd POMPTO 14 FEB 2000

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Christensen et al

Attorney Docket No.: 10450,204-US

Confirmation No: TBA

Serial No · TBA

Group Art Unit: TBA

Filed: February 14, 2006

Examiner: TBA

For: Active-Site Titration of Glycosyl Hydrolases

## INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

This IDS is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application, or before the mailing date of a first Office action on the merits, or before the mailing date of a first Office action after the filling of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: February 14, 2006

Jason I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110 (212)840-0097

0/568243

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known Application Number TBA INFORMATION DISCLOSURE Filing Date February 14, 2006 First Named Inventor STATEMENT BY APPLICANT Christensen et al (use as many sheets as necessary) TBA **Examiner Name** TBA Sheet 12 Attorney Docket Number 10450 204-US

Oncot		01   2	Attori	ley Docket Hullade	10430.204-03
			S PATENT DOCU	0.50170	
			S PATENT DOCU	MENIS	
Examiner Initials	Cite No. 1	Document Number  Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Nome of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pessages or Releven Figures Appear
		US 6,162,614	12-19-2000	Kurihara et al	
				-	<del> </del>
				(4)	
	-				
	_				
	_				-

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.1	Foreign Patent Document  Country Code 3 - Number 4 - Kind Code 8 (if known)	Publication Date MM-DD-YYYY	Neme of Petentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т*
		EP 0104780	04-04-1984	Wako Pure Chemical		
	1	WO 02/10439	02-07-2002	The Gov. of the USA		
		EP 0048989	04-07-1982	Behringwerke		
		WO 01/32844	05-10-2001	Novozymes		
				-		
	<b>†</b>					
	1-					
	1					
					_	
				_		
	-					
		- 199-1				_

Considered "EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conform include copy of this form with next communication to applicant,

Examiner Signature

\*Applicant surings disting dissippation number (options). See trucks Codes of USPTO Patent Documents at your capture part of MEP 50 (A. \*Certor Office that issued to Construct, by the Novelocation Code (WPO Secretard ST.3. \*F. Secretard ST.3. \*F.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the emount of time you are required to complete this form should be sent to the Chief information Office, U.S. Potent and Trademank Office, Weshington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner of Patients, Washington, DC 20031.

IAP9 Racid PCMPTO 14 FEB 2006

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known **Application Number** TBA INFORMATION DISCLOSURE **Filing Date** February 14, 2006 STATEMENT BY APPLICANT First Named Inventor Christensen et al (use as many sheets as necessary) TBA **Examiner Name** TBA Sheet 2 of Attorney Docket Number 10450.204-US

Examiner's	Cite	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	
nitials	No. 1	of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published	T²
		Hansen et al, ChemBiochem, Vol. 1, Part 3, pages 177-180 (2000)	
		Im et al, Carbohydrate Research, Vol. 277, pages 145-159 (1995)	
		Cornish-Bowden, Fundamentals of Enzyme Kinetics, Vol. 11.2, pages 274-277 (1995)	
		Seri et al, Metabolism, Vol. 45, Part 11, pages 1368-1374 (1996)	
		Rotticci et al, Biochimica, Vol. 1483, pages 132-140 (2000)	
		Street et al, Biochemistry, Vol. 31, Part 41, pages 9970-9978 (1992)	
	_		

Evaminer	/Liea I Hobbe/	Date	00000000
-Adminior	/LISA J. HOUUS/	Date	U3/3U/2UU9
Signature	TEROGRAPH TO	Considered	00.00.200

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Nou' Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time vgo ure required to complete this form should be sere to the Chein Information Office, U.S. Patent and Trademark. Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.